From trial design to scientific reporting and regulatory interactions, a drug development program presents unique challenges across several contexts of use. We offer quantitative analyses as a reliable basis for decision-making across all stages of development, from preclinical to post-marketing activities.

Through experience, we are well aware of the swift pace and the many variables to consider before every decision in a drug development program.

With the right support, you can reduce risk and uncertainty along the process, aiding decision-making in a way of working adapted to your specific context of use.

• We know of the challenges in leveraging and analyzing disparate clinical data to better understand both drug and indication properties.

• We understand the importance and challenges of establishing collaboration across disciplines.

• We have helped clients achieve effective decision-making regarding special considerations in trials or analyses involving special populations.

• We are familiar with the short turnarounds and many stakeholders involved in preparing for the end of Phase II meetings, filing after Phase III, or drafting a pediatric investigation plan (PIP).